Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2021 Filed Apr 15, 2021 22:29 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 1,400 | $191.26 | $267,768.20 |
DisclosureSEC source: 0001645113-21-000056 · wf-form4_161852573844212.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,993 F1 · price: On April 13, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 1,400 shares in multiple trades at prices ranging from $191.00 to $191.95. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:01 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 97,973 | $196.34 | $19,236,322.54 |
DisclosureSEC source: 0001645113-21-000055 · wf-form4_161852408765067.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,184 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC |
LEUNG GABRIELDirector
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 6,000 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · derivative · entry 4 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,345 Underlying: Ordinary Shares · 6,000 shares Expires 2028-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC |
LEUNG GABRIELDirector
|
SaleOrdinary Shares | 2,500 | $200.00 | $500,000.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · nonDerivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC |
LEUNG GABRIELDirector
|
SaleOrdinary Shares | 3,500 | $198.01 | $693,035.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,545 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC |
LEUNG GABRIELDirector
|
Exercise / conversionOrdinary Shares | 6,000 | $31.45 | $188,700.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,474 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · derivative · entry 9 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,404 Underlying: Ordinary Shares · 3,474 shares Expires 2030-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 651 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · derivative · entry 8 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,904 Underlying: Ordinary Shares · 651 shares Expires 2029-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,833 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · derivative · entry 7 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,998 Underlying: Ordinary Shares · 1,833 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 3,474 | $200.00 | $694,800.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 6 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOrdinary Shares | 3,474 | $69.37 | $240,991.38 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 5 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 651 | $200.00 | $130,200.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOrdinary Shares | 651 | $83.30 | $54,228.30 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 1,833 | $200.00 | $366,600.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOrdinary Shares | 1,833 | $47.56 | $87,177.48 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:14 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 7,928 | $134.12 | $1,063,303.36 |
DisclosureSEC source: 0001645113-21-000049 · wf-form4_161739444210734.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,393 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:14 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionRestricted Stock Units · Derivative | 9,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000049 · wf-form4_161739444210734.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:14 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionOrdinary Shares | 9,259 | $125.25 | $1,159,689.75 |
DisclosureSEC source: 0001645113-21-000049 · wf-form4_161739444210734.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 16:40 UTC |
Weinberg UriChief Science Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,892 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001645113-21-000048 · wf-form4_161670479191751.xml · derivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,892 Underlying: Ordinary Shares · 3,892 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 16:40 UTC |
Weinberg UriChief Science Officer
|
SaleOrdinary Shares | 3,892 | $140.00 | $544,880.00 |
DisclosureSEC source: 0001645113-21-000048 · wf-form4_161670479191751.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,306 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Weinberg. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 16:40 UTC |
Weinberg UriChief Science Officer
|
Exercise / conversionOrdinary Shares | 3,892 | $47.04 | $183,079.68 |
DisclosureSEC source: 0001645113-21-000048 · wf-form4_161670479191751.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Apr 9, 2021 16:25 UTC Amendment |
Weinberg UriChief Science Officer
|
SaleOrdinary Shares | 2,835 | $140.00 | $396,900.00 |
DisclosureSEC source: 0001645113-21-000051 · wf-form4a_161799991891111.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,471 F1 · security: Amending original form 4 filed on March 25, 2021 to add additional transaction inadvertently omitted. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Weinberg. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:10 UTC |
Shah PriteshChief Commercial Officer
|
SaleRestricted Share Units | 3,524 | $131.09 | $461,961.16 |
DisclosureSEC source: 0001645113-21-000047 · wf-form4_161541063414261.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,272 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 16:08 UTC |
Longsworth Todd ChristopherGeneral Counsel
|
SaleRestricted Share Units | 2,404 | $130.81 | $314,457.62 |
DisclosureSEC source: 0001645113-21-000045 · wf-form4_161541050375020.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,714 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:10 UTC |
Shah PriteshChief Commercial Officer
|
SaleRestricted Share Units | 2,627 | $130.81 | $343,627.36 |
DisclosureSEC source: 0001645113-21-000047 · wf-form4_161541063414261.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,796 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:09 UTC |
Cordova AshleyChief Financial Officer
|
SaleRestricted Share Units | 765 | $130.81 | $100,066.59 |
DisclosureSEC source: 0001645113-21-000046 · wf-form4_161541055936007.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,893 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:07 UTC |
Leonard Frank XChief Development Officer
|
SaleRestricted Share Units | 765 | $130.81 | $100,066.59 |
DisclosureSEC source: 0001645113-21-000044 · wf-form4_161541045494629.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,045 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:06 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleRestricted Share Units | 3,004 | $130.81 | $392,941.22 |
DisclosureSEC source: 0001645113-21-000043 · wf-form4_161541040351233.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,684 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:17 UTC |
Shah PriteshChief Commercial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 13,987 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-21-000042 · wf-form4_161532462367557.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,987 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:17 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 4,550 | $131.53 | $598,461.50 |
DisclosureSEC source: 0001645113-21-000042 · wf-form4_161532462367557.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,423 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:17 UTC |
Shah PriteshChief Commercial Officer
|
Exercise / conversionOrdinary Shares | 13,987 | $7.15 | $100,007.05 |
DisclosureSEC source: 0001645113-21-000042 · wf-form4_161532462367557.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:16 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 2,918 | $131.53 | $383,804.54 |
DisclosureSEC source: 0001645113-21-000041 · wf-form4_161532454290586.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:44 UTC |
Benaim ElyChief Medical Officer
|
SaleRestricted Share Units | 1,888 | $137.55 | $259,701.95 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,177 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:43 UTC |
Shah PriteshChief Commercial Officer
|
SaleRestricted Share Units | 2,658 | $137.55 | $365,618.53 |
DisclosureSEC source: 0001645113-21-000035 · wf-form4_161498420075158.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,986 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:25 UTC |
Longsworth Todd ChristopherGeneral Counsel
|
SaleRestricted Share Units | 3,084 | $137.55 | $424,216.54 |
DisclosureSEC source: 0001645113-21-000039 · wf-form4_161523872602441.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,118 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:26 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleRestricted Share Units | 3,854 | $137.55 | $530,133.12 |
DisclosureSEC source: 0001645113-21-000040 · wf-form4_161523876525004.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,688 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:24 UTC |
Leonard Frank XChief Development Officer
|
SaleRestricted Share Units | 567 | $137.55 | $77,993.12 |
DisclosureSEC source: 0001645113-21-000038 · wf-form4_161523866603519.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,810 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:23 UTC |
Cordova AshleyChief Financial Officer
|
GiftOrdinary Shares | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000037 · wf-form4_161523857594813.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,658 F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:23 UTC |
Cordova AshleyChief Financial Officer
|
SaleRestricted Share Units | 567 | $137.55 | $77,993.12 |
DisclosureSEC source: 0001645113-21-000037 · wf-form4_161523857594813.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,568 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:44 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,475 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · derivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,878 Underlying: Ordinary Shares · 3,475 shares Expires 2030-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:44 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 3,475 | $150.78 | $523,960.50 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,065 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:44 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOrdinary Shares | 3,475 | $69.37 | $241,060.75 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:43 UTC |
Shah PriteshChief Commercial Officer
|
SaleRestricted Share Units | 2,174 | $150.78 | $327,795.72 |
DisclosureSEC source: 0001645113-21-000035 · wf-form4_161498420075158.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,644 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:54 UTC |
Weinberg UriChief Science Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 16,003 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000032 · wf-form4_161489844997400.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,003 Underlying: Ordinary Shares · 16,003 shares Expires 2031-03-01 F2 · derivative.exercise_date: Options to buy 16,003 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:54 UTC |
Weinberg UriChief Science Officer
|
GrantRestricted Share Units | 8,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000032 · wf-form4_161489844997400.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,306 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:44 UTC |
Longsworth Todd ChristopherGeneral Counsel
|
GrantOptions to Buy Ordinary Shares · Derivative | 19,004 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000026 · wf-form4_161489786798435.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,004 Underlying: Ordinary Shares · 19,004 shares Expires 2031-03-01 F3 · derivative.exercise_date: Options to buy 19,004 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:44 UTC |
Longsworth Todd ChristopherGeneral Counsel
|
GrantRestricted Share Units | 10,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000026 · wf-form4_161489786798435.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,202 F2 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:44 UTC |
Longsworth Todd ChristopherGeneral Counsel
|
SaleRestricted Share Units | 2,355 | $152.05 | $358,084.82 |
DisclosureSEC source: 0001645113-21-000026 · wf-form4_161489786798435.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,860 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on February 27, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:53 UTC |
Benaim ElyChief Medical Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 16,003 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000031 · wf-form4_161489839039798.xml · derivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,003 Underlying: Ordinary Shares · 16,003 shares Expires 2031-03-01 F2 · derivative.exercise_date: Options to buy 16,003 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:53 UTC |
Benaim ElyChief Medical Officer
|
GrantRestricted Share Units | 8,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000031 · wf-form4_161489839039798.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,065 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.